These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11524494)

  • 1. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Filippi M; Rovaris M; Rocca MA; Sormani MP; Wolinsky JS; Comi G;
    Neurology; 2001 Aug; 57(4):731-3. PubMed ID: 11524494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
    Zivadinov R; Dwyer M; Barkay H; Steinerman JR; Knappertz V; Khan O
    J Neurol; 2015 Mar; 262(3):648-53. PubMed ID: 25542295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Richert ND
    Neurology; 2002 May; 58(9):1440-1; author reply 1441-2. PubMed ID: 12011306
    [No Abstract]   [Full Text] [Related]  

  • 4. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.
    Cadavid D; Cheriyan J; Skurnick J; Lincoln JA; Wolansky LJ; Cook SD
    J Neurol Neurosurg Psychiatry; 2009 Dec; 80(12):1337-43. PubMed ID: 19687024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
    Arnold DL; Campagnolo D; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Vollmer T
    J Neurol; 2008 Oct; 255(10):1473-8. PubMed ID: 18854910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G; Filippi M; Wolinsky JS
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
    Filippi M; Wolinsky JS; Comi G;
    Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
    Weinstein A; Schwid SR; Schiffer RB; McDermott MP; Giang DW; Goodman AD
    Arch Neurol; 1999 Mar; 56(3):319-24. PubMed ID: 10190822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetization transfer imaging of acute black holes in patients on glatiramer acetate.
    Zivadinov R; Hussein S; Bergsland N; Minagar A; Dwyer MG
    Front Biosci (Elite Ed); 2012 Jan; 4(4):1496-504. PubMed ID: 22201970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
    Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
    Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.
    Selmaj K; Barkhof F; Belova AN; Wolf C; van den Tweel ER; Oberyé JJ; Mulder R; Egging DF; Koper NP; Cohen JA;
    Mult Scler; 2017 Dec; 23(14):1909-1917. PubMed ID: 28090798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.
    Qin Y; Zhang DQ; Prat A; Pouly S; Antel J
    J Neuroimmunol; 2000 Aug; 108(1-2):201-6. PubMed ID: 10900354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
    Rovaris M; Comi G; Rocca MA; Valsasina P; Ladkani D; Pieri E; Weiss S; Shifroni G; Wolinsky JS; Filippi M;
    Mult Scler; 2007 May; 13(4):502-8. PubMed ID: 17483532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.
    Ge Y; Grossman RI; Udupa JK; Fulton J; Constantinescu CS; Gonzales-Scarano F; Babb JS; Mannon LJ; Kolson DL; Cohen JA
    Neurology; 2000 Feb; 54(4):813-7. PubMed ID: 10690968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.